{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:56:21Z","timestamp":1792205781617,"version":"4.4.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>With the medical use of cannabis permitted in Canada since 2001, patients seek to use this botanical drug to treat a range of medical conditions. However, many healthcare practitioners express the need for further scientific evidence around the use of medical cannabis. This real-world evidence study aimed to address the paucity of scientific data by surveying newly registered medical cannabis patients, before beginning medical cannabis treatment, and at one follow up 6 weeks after beginning medical cannabis treatment. The goal was to collect data on efficacy, safety and cannabis product type information to capture the potential impact medical cannabis had on patient-reported quality of life (QOL) and several medical conditions over a 6-week period using validated questionnaires. The 214 participants were mainly male (58%) and 57% of the population was older than 50. The most frequently reported medical conditions were recurrent pain, post-traumatic stress disorder (PTSD), anxiety, sleep disorders [including restless leg syndrome (RLS)], and arthritis and other rheumatic disorders. Here we report that over 60% of our medical cannabis cohort self-reported improvements in their medical conditions. With the use of validated surveys, we found significant improvements in recurrent pain, PTSD, and sleep disorders after 6 weeks of medical cannabis treatment. Our findings from patients who reported arthritis and other rheumatic disorders are complex, showing improvements in pain and global activity sub-scores, but not overall changes in validated survey scores. We also report that patients who stated anxiety as their main medical condition did not experience significant changes in their anxiety after 6 weeks of cannabis treatment, though there were QOL improvements. While these results show that patients find cannabis treatment effective for a broad range of medical conditions, cannabis was not a remedy for all the conditions investigated. Thus, there is a need for future clinical research to support the findings we have reported. Additionally, while real-world evidence has not historically been utilized by regulatory bodies, we suggest changes in public policy surrounding cannabis should occur to reflect patient reported efficacy of cannabis from real-world studies due to the uniqueness of medical cannabis's path to legalization.<\/jats:p>","DOI":"10.3389\/fpubh.2021.626853","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:29:15Z","timestamp":1621470555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Evaluation of Patient Reported Safety and Efficacy of Cannabis From a Survey of Medical Cannabis Patients in Canada"],"prefix":"10.3389","volume":"9","author":[{"given":"Shaina P.","family":"Cahill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-2189-5","volume-title":"Marihuana: The First Twelve Thousand Years","author":"Abel","year":"1980"},{"key":"B2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/095952874302600116","article-title":"Observations on the medicinal properties of the Cannabis Sativa of India","volume":"26","author":"Clendinning","year":"1843","journal-title":"Med Chir Trans."},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1126\/science.162.3859.1234","article-title":"Clinical and psychological effects of marijuana in man","volume":"4","author":"Weil","year":"1969","journal-title":"Int J Addict."},{"key":"B4","volume-title":"Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance From the College of Family Physicians of Canada","year":"2014"},{"key":"B5","volume-title":"Cannabis for Medical Purposes\u2014Advice to the Profession","year":"2014"},{"key":"B6","volume-title":"Practice Standard: Cannabis for Medical Purposes","year":"2019"},{"key":"B7","volume-title":"Ordonnance de Cannabis A des fins medicales","year":"2018"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/head.13345","article-title":"Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science","volume":"58","author":"Baron","year":"2018","journal-title":"Headache."},{"key":"B9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/plants8110496","article-title":"Highly predictive genetic markers distinguish drug-type from fiber-type cannabis sativa L","volume":"8","author":"Cascini","year":"2019","journal-title":"Plants."},{"key":"B10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.forsciint.2013.05.019","article-title":"Analysis of THCA synthase gene expression in cannabis: a preliminary study by real-time quantitative PCR","volume":"231","author":"Cascini","year":"2013","journal-title":"Forensic Sci Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.177.4043.62","article-title":"11-Hydroxy-\u03949-tetrahydrocannabinol:-pharmacology, disposition, and metabolism of a major metabolite of marihuana in man","volume":"177","author":"Lemberger","year":"1972","journal-title":"Science."},{"key":"B12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0006-8993(91)91239-w","article-title":"Differential effects of \u03949-tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells","volume":"560","author":"Turkanis","year":"1991","journal-title":"Brain Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jat\/bkx012","article-title":"Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes","volume":"41","author":"Vandrey","year":"2017","journal-title":"J Anal Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2011.01238.x","article-title":"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo","year":"2011","journal-title":"Br J Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2147\/JPR.S192174","article-title":"Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry","volume":"12","author":"Ueberall","year":"2019","journal-title":"J Pain Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3732\/ajb.91.6.966","article-title":"A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)","volume":"91","author":"Hillig","year":"2004","journal-title":"Am J Bot."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","article-title":"Effects of cannabidiol (CBD) on regional cerebral blood flow","volume":"29","author":"Crippa","year":"2004","journal-title":"Neuropsychopharmacology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life","volume":"8","author":"Zuardi","year":"2017","journal-title":"Front Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1017\/S1461145709990617","article-title":"Modulation of effective connectivity during emotional processing by \u03949-tetrahydrocannabinol and cannabidiol","volume":"13","author":"Fusar-Poli","year":"2010","journal-title":"Int J Neuropsychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of \u03949-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch Gen Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1038\/npp.2013.97","article-title":"Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers","volume":"38","author":"Cooper","year":"2013","journal-title":"Neuropsychopharmacology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jpain.2007.10.018","article-title":"Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy","volume":"9","author":"Narang","year":"2008","journal-title":"J Pain."},{"key":"B25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00482-019-00399-z","article-title":"Accompanying survey on the use of cannabis medicines in Germany-interim evaluation","volume":"62","author":"Schmidt-Wolf","year":"2019","journal-title":"Fed Heal Gaz."},{"key":"B26","first-page":"375","article-title":"Efficacy of different varieties of medical cannabis in relieving symptoms","volume":"10","author":"Wan","year":"2017","journal-title":"J Pain Manag."},{"key":"B27","doi-asserted-by":"publisher","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jpain.2015.07.014","article-title":"Cannabis for the management of pain: assessment of safety study (COMPASS)","volume":"16","author":"Ware","year":"2015","journal-title":"J Pain."},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.pain.2004.09.013","article-title":"Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial","volume":"112","author":"Berman","year":"2004","journal-title":"Pain."},{"key":"B30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2010","journal-title":"J Pain Symptom Manage."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.clinthera.2007.09.013","article-title":"Oromucosal \u03949-tetrahydrocannabinol\/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial","volume":"29","author":"Rog","year":"2007","journal-title":"Clin Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/JPR.S160556","article-title":"Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases","volume":"11","author":"Darkovska-Serafimovska","year":"2018","journal-title":"J Pain Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"J Psychiatr Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/npp.2011.188","article-title":"Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm","volume":"37","author":"Uribe-Mari\u00f1o","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.neuropharm.2011.08.013","article-title":"Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats","volume":"62","author":"Hsiao","year":"2012","journal-title":"Neuropharmacology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bbr.2006.05.016","article-title":"Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats","volume":"172","author":"Resstel","year":"2006","journal-title":"Behav Brain Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/npp.2012.63","article-title":"On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment","volume":"37","author":"Stern","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbr.2009.09.045","article-title":"Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats","volume":"207","author":"Lemos","year":"2010","journal-title":"Behav Brain Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fnbeh.2019.00091","article-title":"The divergent effects of CDPPB and cannabidiol on fear extinction and anxiety in a predator scent stress model of PTSD in rats","volume":"13","author":"Shallcross","year":"2019","journal-title":"Front Behav Neurosci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/da.22954","article-title":"Interactive effects of PTSD and substance use on suicidal ideation and behavior in military personnel: increased risk from marijuana use","volume":"36","author":"Allan","year":"2019","journal-title":"Depress Anxiety."},{"key":"B41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jad.2020.05.132","article-title":"Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder","volume":"274","author":"LaFrance","year":"2020","journal-title":"J Affect Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/da.22947","article-title":"Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: results from an American nationally representative study","volume":"36","author":"Bilevicius","year":"2019","journal-title":"Depress Anxiety."},{"key":"B43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol Group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy."},{"key":"B44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","article-title":"A time trade-off-derived value set of the EQ-5D-5L for Canada","volume":"54","author":"Xie","year":"2016"},{"key":"B45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1682\/jrrd.2003.09.0381","article-title":"Development and validation of the pain outcomes","volume":"40","author":"Clark","year":"2003","journal-title":"J Rehabil Res Dev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/jclp.21908","article-title":"The depression anxiety stress scales-21 (DASS-21): further examination of dimensions, scale reliability, and correlates","volume":"68","author":"Osman","year":"2012","journal-title":"J Clin Psychol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1348\/014466505X29657","article-title":"The short-form version of the depression anxiety stress scales (DASS-21): construct validity and normative data in a large non-clinical sample","volume":"44","author":"Henry","year":"2005","journal-title":"Br J Clin Psychol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3899\/jrheum.100008","article-title":"The Patient Activity Scale-ii is a generic indicator of active disease in patients with rheumatic disorders","volume":"37","author":"Parekh","year":"2010","journal-title":"J Rheumatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00004850-200109000-00005","article-title":"SPRINT: A brief global assessment of post-traumatic stress disorder","volume":"16","author":"Connor","year":"2001","journal-title":"Int Clin Psychopharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7517-2-18","article-title":"Survey of Australians using cannabis for medical purposes","volume":"2","author":"Swift","year":"2005","journal-title":"Harm Reduct J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5694\/mja17.01247","article-title":"Medicinal cannabis in Australia, 2016: The Cannabis as Medicine Survey (CAMS-16)","volume":"209","author":"Lintzeris","year":"2018","journal-title":"Med J Aust."},{"key":"B54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1300\/J175v03n02_03","article-title":"Survey on the medical use of cannabis and THC in Germany","volume":"3","author":"Grotenhermen","year":"2003","journal-title":"J Cannabis Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/02791072.2000.10400245","article-title":"Who is using cannabis as a medicine and why: an exploratory study","volume":"32","author":"Ogbome","year":"2000","journal-title":"J Psychoactive Drugs."},{"key":"B56","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1742-1241.2004.00271.x","article-title":"The medicinal use of cannabis in the UK: results of a nationwide survey","volume":"59","author":"Ware","year":"2005","journal-title":"Int J Clin Pract."},{"key":"B57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0304-3959(02)00400-1","article-title":"Cannabis use for chronic non-cancer pain: results of a prospective survey","volume":"102","author":"Ware","year":"2003","journal-title":"Pain."},{"key":"B58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2018.0036","article-title":"A Description of the medical cannabis use in Ontario, Canada","volume":"4","author":"Eurich","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1533210107301834","article-title":"Medical Cannabis patients: patient profiles and health care utilization patterns","volume":"12","author":"Reiman","year":"2007","journal-title":"Complement Health Pract Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/02791072.2011.587700","article-title":"Who are medical marijuana patients? Population characteristics from nine California assessment clinics","volume":"43","author":"Reinarman","year":"2011","journal-title":"J Psychoactive Drugs."},{"key":"B61","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.drugpo.2013.08.010","article-title":"Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use","volume":"24","author":"Walsh","year":"2013","journal-title":"Int J Drug Policy."},{"key":"B62","unstructured":"Census: National Household Survey (NHS) Profile2016"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e0187795","DOI":"10.1371\/journal.pone.0187795","article-title":"Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study","volume":"12","author":"Vigil","year":"2017","journal-title":"PLoS ONE."},{"key":"B64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugpo.2017.01.011","article-title":"Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients","volume":"42","author":"Lucas","year":"2017","journal-title":"Int J Drug Policy."},{"key":"B65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2147\/JPR.S134330","article-title":"Cannabis as a substitute for prescription drugs- a cross-sectional study","volume":"10","author":"Corroon","year":"2017","journal-title":"J Pain Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fphar.2018.01259","article-title":"Cannabinoids and pain: new insights from old molecules","volume":"9","author":"Vu\u010dkovic","year":"2018","journal-title":"Front Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","article-title":"The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain","volume":"556","author":"Costa","year":"2007","journal-title":"Eur J Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of \u03949-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br J Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/ptr.2401","article-title":"Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved","volume":"22","author":"Comelli","year":"2008","journal-title":"Phyther Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/j.pain.0000000000001386","article-title":"Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain","volume":"160","author":"De Gregorio","year":"2019","journal-title":"Pain."},{"key":"B71","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1089\/can.2018.0014","article-title":"The anti-inflammatory properties of terpenoids from Cannabis","volume":"3","author":"Gallily","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejp.818","article-title":"Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis","volume":"20","author":"Hammell","year":"2016","journal-title":"Eur J Pain."},{"key":"B73","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00210-004-0871-3","article-title":"Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw","volume":"369","author":"Costa","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pnpbp.2017.07.012","article-title":"Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative","volume":"79","author":"Silva","year":"2017","journal-title":"Prog NeuroPsychopharmacology Biol Psychiatry."},{"key":"B75","first-page":"337","article-title":"Patient characteristics from a medical cannabis provider","volume":"10","author":"Wan","year":"2017","journal-title":"J Pain Manag."},{"key":"B76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/02791072.2013.805976","article-title":"The medicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms","volume":"45","author":"Hazekamp","year":"2013","journal-title":"J Psychoactive Drugs."},{"key":"B77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","article-title":"A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy","volume":"1","author":"Sexton","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA."},{"key":"B79","volume-title":"The Health Effects of Cannabis and Cannabinoids : The Current State of Evidence and Recommendations for Research","year":"2017"},{"key":"B80","first-page":"397","article-title":"Medical cannabis use in military and police veterans diagnosed with post-traumatic stress disorder (PTSD)","volume":"10","author":"Smith","year":"2017","journal-title":"J Pain Manag."},{"key":"B81","first-page":"10","article-title":"Efficacy of different varieties of medical cannabis in relieving symptoms in post-traumatic stress disorder (PTSD) patients","author":"Drost","year":"2017","journal-title":"J Pain Manag."},{"key":"B82","first-page":"385","article-title":"Medical cannabis use for patients with post-traumatic stress disorder (PTSD)","volume":"10","author":"Chan","year":"2017","journal-title":"J Pain Manag."},{"key":"B83","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology."},{"key":"B84","first-page":"407","article-title":"The effect of medical cannabis on alcohol and tobacco use in veterans with post-traumatic stress disorder (PTSD)","volume":"10","author":"Jin","year":"2017","journal-title":"J Pain Manag."},{"key":"B85","first-page":"363","article-title":"The use of medical cannabis in common medical conditions excluding cancer","volume":"10","author":"Zaki","year":"2017","journal-title":"J Pain Manag."},{"key":"B86","doi-asserted-by":"publisher","first-page":"86","DOI":"10.9740\/mhc.2018.03.086","article-title":"A review of medical marijuana for the treatment of posttraumatic stress disorder: real symptom re-leaf or just high hopes?","volume":"8","author":"Shishko","year":"2018","journal-title":"Ment Heal Clin."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.addbeh.2006.09.010","article-title":"Marijuana motives: young adults' reasons for using marijuana","volume":"32","author":"Lee","year":"2007","journal-title":"Addict Behav."},{"key":"B88","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/02791072.2019.1626953","article-title":"Use of cannabis to relieve pain and promote sleep by customers at an adult use dispensary","volume":"51","author":"Bachhuber","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"B89","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1037\/pha0000285","article-title":"The use of cannabinoids for sleep: a critical review on clinical trials","volume":"27","author":"Kuhathasan","year":"2019","journal-title":"Exp Clin Psychopharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1097\/j.pain.0000000000001052","article-title":"Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis","volume":"158","author":"Philpott","year":"2017","journal-title":"Pain."},{"key":"B91","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1073\/pnas.160105897","article-title":"The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis","volume":"97","author":"Malfait","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B92","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/rheumatology\/kei183","article-title":"Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis","volume":"45","author":"Blake","year":"2006","journal-title":"Rheumatology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fnins.2018.00730","article-title":"Cannabis and the anxiety of fragmentation\u2014a systems approach for finding an anxiolytic cannabis chemotype","volume":"12","author":"Kamal","year":"2018","journal-title":"Front Neurosci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety","volume":"7","author":"Zuardi","year":"1993","journal-title":"J Psychopharmacol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12888-019-2324-z","article-title":"Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments","volume":"19","author":"Yau","year":"2019","journal-title":"BMC Psychiatry."},{"key":"B96","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in anxiety and sleep: a large case series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm J."},{"key":"B97","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.gore.2019.100497","article-title":"Non-prescription cannabis use for symptom management amongst women with gynecologic malignancies","volume":"30","author":"Blake","year":"2019","journal-title":"Gynecol Oncol Rep."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.626853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:29:24Z","timestamp":1621470564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.626853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":97,"alternative-id":["10.3389\/fpubh.2021.626853"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.626853","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"article-number":"626853"}}